BIOMAT Database Logo BIOMAT Database Logo

Negative symptoms and neuroleptics in catatonic schizophrenia. 2003

Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Department of Psychiatry, University of Turku, FIN-20520 Turku, Finland. Raimo.K.R.Salokangas@tyks.fi

The association between neuroleptic treatment and the negative symptom dimension (ND) was evaluated in 1528 schizophrenia patients. In patients receiving more than 820 mg chlorpromazine (CPZ), those with catatonic-type disorder had significantly (p<0.05) higher ND scores than those in any of the other diagnostic subtypes. Even in patients receiving 450 mg CPZ or more, catatonic patients had significantly (p=0.046) higher ND scores than other patients. Patients with catatonic schizophrenia are highly vulnerable to negative symptoms related to neuroleptic drugs, probably because of a defect in their dopaminergic neuronal pathways.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D012560 Schizophrenia, Catatonic A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture. Catatonic Schizophrenia,Catatonic Schizophrenias,Schizophrenias, Catatonic

Related Publications

Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Catatonic schizophrenia and negative symptoms.
March 1987, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
[Treatment of negative symptoms in schizophrenia with neuroleptics].
January 1989, L'Encephale,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Negative and deficit symptoms in schizophrenia do respond to neuroleptics.
January 1985, Schizophrenia bulletin,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited.
December 1999, Schizophrenia research,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Schizophrenia and toxoplasmosis: association with catatonic symptoms.
September 2020, Consortium psychiatricum,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
December 1986, Journal of clinical psychopharmacology,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.
January 1980, Psychopharmacology,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
[Behavioral assessment of neuroleptics (3)--Schizophrenia negative symptoms-like model induced by PCP].
August 1996, Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia.
January 1989, Drugs under experimental and clinical research,
Raimo K R Salokangas, and Teija Honkonen, and Eija Stengård, and Anna Maija Koivisto, and Jarmo Hietala
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
August 1995, The American journal of psychiatry,
Copied contents to your clipboard!